Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New app aims to turn wearable data into diabetes Self-Care success

NCT ID NCT06848361

Symptom relief Sponsor: Ann-Marie Rosland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 16, 2026 · Updated 5 times

Summary

This pilot study tests MPowerHub, a smartphone app that helps adults with type 2 diabetes make sense of data from continuous glucose monitors and activity trackers. The app shows combined trends and prompts daily questions about diet, sleep, stress, and medication. Researchers want to see if people will use the app and stick with it for 4 months. If it works, this could lead to better diabetes management and fewer complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MPowerHub app (behavioral intervention using wearable device data)
What this could lead to
If successful, this approach could help people with type 2 diabetes better manage their condition using data from wearable devices, potentially reducing complications and improving quality of life.
What could go wrong
This is a small pilot study (80 participants) focused on feasibility, not on proving health outcomes. The app may not lead to lasting behavior change or improved blood sugar control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Received outpatient care in the participating health system in the last 12 months * Has a diagnosis of type 2 diabetes mellitus (ICD10 codes E08.xx, E09.xx, E11.xx, E13.xx,O24.1x , O24.3x, O24.8x, O24.9x) * Last Hemoglobin A1c (HbA1c) value obtained in the last 6 months was ≥7.5% * Currently prescribed at least one non-insulin diabetes medication * Able to provide informed consent * Able to interact with a simple smartphone application * Owns or has access to a smartphone that is able to access an internet website * Did not participate a prior study related to this protocol Exclusion Criteria: * Originally was diagnosed with type 2 diabetes before the age of 21 years * Has a diagnosis of type 1 diabetes mellitus * Has a diagnosis of gestational diabetes without any other diabetes diagnoses * Is currently prescribed insulin * Currently is using a CGM device * Has a diagnosis (active or prior) of schizophrenia or other psychotic/delusional disorder * Has a life-limiting severe illness (e.g., chronic obstructive pulmonary disease requiring oxygen) * Is pregnant or planning to become pregnant within the next 6 months * Has other concerns that may interfere significantly with their ability to participate in the intervention (ongoing health issues, personal events, etc.) * Currently is enrolled in another diabetes management intervention study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus (T2DM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Empowerment type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes mellitus (T2DM)

Contacts and locations

Locations

  • University of Pittsburgh

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.